Insu Therapeutics is advancing needle-free peptide therapies through its investigational InsuTab and BuccaGLP formulations, designed to deliver insulin and semaglutide without injections. The technology uses layered tablets that attach to the inner cheek, releasing medication toward surrounding tissue for absorption. Unlike swallowed treatments, the approach bypasses gastrointestinal absorption and reportedly requires no fasting or dietary restrictions around dosing. A recent U.S. patent allowance strengthens protection for the delivery system, following laboratory, cell-culture, and animal research conducted at the University of British Columbia.
The development creates potential opportunities for Insu and strategic investor Hydreight within the pharmaceutical market. Hydreight holds U.S. distribution rights and operates healthcare infrastructure connecting providers, pharmacies, and patients nationwide. Successful development could support future licensing agreements and commercial partnerships. However, both formulations remain unapproved, with further testing required to establish their safety and effectiveness.
Image Credit: Hydreight Technologies Inc.
Key Themes Behind This Trend
- Needle-free Biologics
- Cheek-adhering delivery systems signal new market potential for biologics that reduce injection dependence and improve treatment convenience.
- Buccal Peptide Delivery
- Layered tablet platforms create alternatives to gastrointestinal absorption, expanding how fragile peptide drugs can be formulated and commercialized.
- Patient-friendly Diabetes Care
- Simplified dosing without fasting or needles reflects growing demand for chronic disease therapies designed around adherence and daily usability.
Where This Applies
- Pharmaceuticals
- Patent-protected delivery formats may reshape competitive positioning for insulin, GLP-1, and other peptide-based therapeutic portfolios.
- Digital Health
- Provider-pharmacy-patient networks offer infrastructure for distributing emerging therapies through more connected care and fulfillment models.
- Biotechnology
- Translational research in oral-mucosal absorption supports platform innovation across preclinical development, licensing, and specialty drug commercialization.
